DESTINY-Breast05 Trial

CHMP Recommends Expanding Enhertu Label to Add Adjuvant Use

The recommendation would allow adjuvant treatment for selected resected HER2‑positive early breast cancers while a European Commission decision and an updated product label are awaited.